Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

Researchers at the University of Illinois at Chicago College of Medicine have found that a growth factor can regenerate damaged peripheral nerves without causing the growth of new blood vessels -- making it a unique candidate to treat nerve damage in areas of the body where the proliferation of blood vessels would be a drawback.

18 Nov 2014

University of Leeds researchers make new synthetic anti-cancer molecule

Researchers at the University of Leeds have made a new synthetic anti-cancer molecule that targets two key mechanisms in the spread of malignant tumours through the body.

13 Nov 2014

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

In a potential breakthrough against ovarian cancer, University of Guelph researchers have discovered how to both shrink tumours and improve drug delivery, allowing for lower doses of chemotherapy and reducing side effects.

13 Nov 2014

New treatment could halt growth of tumours in prostate cancer patients

Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer.

11 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Seno Imagio breast imaging system and associated predictive model can help eliminate breast biopsies

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced that the use of the Seno Imagio breast imaging system and the associated predictive model appear to have the potential to significantly improve the physicians’ ability to accurately rule out breast cancer compared to traditional ultrasound alone.

4 Nov 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Seno Medical completes enrollment in PIONEER Pivotal Study of Imagio for diagnosing breast cancer

24 Sep 2014

Photoacoustics could become alternative to mammography or sonogram for breast cancer detection

One of the lines of research of OILTEBIA, a European science project coordinated by Universidad Carlos III de Madrid, is a method to detect breast cancer based on photoacoustics and which could become an alternative to mammography or sonogram.

22 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest.

17 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal.

11 Sep 2014

Transplantation of B10 cells helps inhibit development of bladder fibrosis post SCI

A team of researchers from Korea and Canada have found that transplantation of B10 cells (a stable immortalized human bone marrow derived -mesenchymal stem cell line; B10 hMSC) directly into the bladder wall of mice modeled with spinal cord injury (SCI) helped inhibit the development of bladder fibrosis and improved bladder function by promoting the growth of smooth muscle cells in the bladder.

4 Sep 2014

Angiogenesis News and Research

Further Reading

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

University of Leeds researchers make new synthetic anti-cancer molecule

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

New treatment could halt growth of tumours in prostate cancer patients

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Seno Imagio breast imaging system and associated predictive model can help eliminate breast biopsies

NCCN ORP awards four research grants to advance development of nintedanib

Seno Medical completes enrollment in PIONEER Pivotal Study of Imagio for diagnosing breast cancer

Photoacoustics could become alternative to mammography or sonogram for breast cancer detection

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Professor receives award for development of anti-angiogenic therapy for retinal disease

Transplantation of B10 cells helps inhibit development of bladder fibrosis post SCI

KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Experts open new clinic to evaluate heart disease patients for participation in stem cell studies

Study: Brain tumors hijack the brain's existing blood supply during progression

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo